therapeutics glp 1 activate Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Central glucagon-like peptide 1 receptor

Although periconceptional exposure to GLP-1 receptor agonists has not shown an increased risk of malformations, data on complications such as fetal growth restriction or embryonic death are lacking [188]

Cold Spring Harbor perspectives in medicine 2018;8

These included CT-996, a once-daily oral small-molecule oral GLP-1 receptor agonist, in Phase I, for treating obesity in patients with and without Type 2 diabetes, as well as two injectable clinical drug candidates: CT-388, a once-weekly subcutaneous injectable in Phase II, for treating obesity in patients with and without Type 2 diabetes, and CT-868, a once-daily subcutaneous injectable, in Phase II, for treating Type 1 diabetes patients with overweight or obesity

Sometimes a different class of medication works better for your body or lifestyle

doi: 10.1007/s13679-023-00536-x